Related Experiment Video
Updated: Mar 25, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Intra-species competition combats vancomycin-resistant enterococci
Nadav Ben-Assa1, Rawi Naddaf1, Shaqed Carasso1
1Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine and Research Institute, Rappaport Technion Integrated Cancer Center (RTICC), Technion-Israel Institute of Technology, Haifa, Israel.
Abstract:
Vancomycin-resistant Enterococcus (VRE) is a leading cause of multidrug-resistant infections in hospitalized patients, yet no reproducible microbiota therapies exist to selectively displace it. Here we harness intra-species competition within Enterococcus to suppress VRE colonization. Through in vitro screening and mouse colonization models, we identified a single antibiotic-susceptible strain, E. faecalis X98, that significantly reduced VRE burden both in vitro and in mouse experiments, whereas multi-strain consortia failed due to competitive interference among consortium members. In parallel, we subjected the vancomycin-sensitive strain E. faecalis OG1RF to phage selection, which produced a prophage-integrated derivative with convergent glycosyltransferase mutations that secreted a VRE-killing factor, conferring enhanced antagonism even without exogenous phage. These findings reveal ecological and evolutionary principles for selecting strains as targeted microbial therapeutics. Exploiting intra-species antagonism and phage-driven evolution provides a practical framework for developing microbiota-based interventions that minimize collateral damage to the microbiome while addressing antibiotic-resistant pathogens.
Insights
Researchers identified a single, antibiotic-susceptible Enterococcus strain that effectively suppresses vancomycin-resistant Enterococcus (VRE) colonization. This approach harnesses natural competition to combat multidrug-resistant infections, offering a targeted microbiome therapy.
Area of Science:
- Microbiology
- Microbiome Therapeutics
- Infectious Diseases
Background:
- Vancomycin-resistant Enterococcus (VRE) is a major cause of hospital-acquired infections.
- Existing treatments lack reproducible microbiota therapies to selectively eliminate VRE.
- Developing targeted interventions against VRE is crucial for public health.
Purpose of the Study:
- To identify a specific bacterial strain capable of suppressing VRE colonization.
- To explore the use of intra-species competition for developing VRE microbiota therapies.
- To investigate phage-driven evolution for enhancing VRE antagonism.
Main Methods:
- Conducted in vitro screening and mouse colonization models to identify VRE-suppressing strains.
- Utilized phage selection on a vancomycin-sensitive Enterococcus strain.
- Analyzed genetic mutations and secreted factors responsible for VRE antagonism.
Main Results:
- A single antibiotic-susceptible strain, E. faecalis X98, significantly reduced VRE burden in vitro and in vivo.
- Multi-strain consortia were less effective due to competitive interference.
- Phage-selected E. faecalis OG1RF derivatives exhibited enhanced VRE antagonism via secreted factors.
Conclusions:
- Intra-species competition can be harnessed to select effective VRE-suppressing strains.
- Phage-driven evolution offers a strategy to enhance microbial therapeutics.
- This framework provides a practical approach for developing targeted microbiome interventions against antibiotic-resistant pathogens with minimal collateral damage.
Related Concept Videos
Microbial Interactions: Competition
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Competition
Antibiotic Selection

